Temat: pasireotide - Katalog OPAC zbiorów

Skocz do pozycji: 1.

Tytuł:: Cushing’s disease: is pasireotide LAR a breakthrough in adjuvant therapy after unsuccessful surgery?
Autorzy:: Witek, Przemysław
Mazur, Marta
Witek, Joanna
Powiązania:: https://bibliotekanauki.pl/articles/1062550.pdf
Data publikacji:: 2017
Wydawca:: Medical Education
Tematy:: Cushing’s disease
corticotrophin
cortisol
diabetes
pasireotide
Opis:: Cushing’s disease is a rare endocrine disorder caused by ACTH-secreting pituitary adenoma. The treatment of choice is a transsphenoidal surgery performed by an experienced neurosurgeon. However, in some patients adjuvant treatment is required due to ineffective surgery or disease recurrence. This article discusses new aspects of pharmacological treatment of ACTH-dependent hypercortisolism in light of a recent publication reporting the efficacy and safety of once a month pasireotide LAR injections in Cushing’s disease.
Źródło:: OncoReview; 2017, 7, 4; 176-179
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Skocz do pozycji: 2.

Tytuł:: Acromegaly: the effect of somatostatin analogues on tumour volume shrinkage
Autorzy:: Witek, Przemysław
Gutowska, Marta
Powiązania:: https://bibliotekanauki.pl/articles/1064786.pdf
Data publikacji:: 2016
Wydawca:: Medical Education
Tematy:: acromegaly
growth hormone
insulin-like growth factor 1
lanreotide
long-acting somatostatin analogues
octreotide
pasireotide
somatotroph pituitary adenoma
tumour volume reduction
Opis:: Acromegaly is a rare disease, caused by growth hormone (GH) hypersecretion and secondarily elevated insulin-like growth factor 1 (IGF-1) level. Nearly all patients with acromegaly suffer from somatotroph pituitary adenoma. The main goal of treatment is to normalise both GH and IGF-1 levels, which reduces symptoms, complications and mortality. Transsphenoidal selective adenomectomy performed by an experienced neurosurgeon is the first-line therapy. Therapy with somatostatin analogues (SSA) is used as a neoadjuvant treatment prior to surgery and in a persistent disease following the surgery. The long-acting somatostatin analogues reduce serum GH/IGF-1 levels and tumour volume. In this clinical review, mechanisms and role of 1st and 2nd generation somatostatin analogues in the treatment of patients with acromegaly are presented, with particular emphasis on the effects on somatotroph pituitary adenoma volume reduction.
Źródło:: OncoReview; 2016, 6, 4; A162-168
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki

Artykuł

Zmień widok

na półce

Informacja

Wyszukujesz frazę "pasireotide" wg kryterium: Temat

Źródło danych

Dostawca treści

Kolekcja

Rok wydania

Wydawca

Temat

Autor

Typ dokumentu

Język